The Complete Review and Analysis of the Chimeric Antigen T Cell Receptors (CART-T) Programs and All the Main Players in the Pharmaceutical & Biotechnology Industry in 2018
Chimeric antigen receptors (CARs) are engineered receptors that are changed in the laboratory to combine as a new specificity with an immune cell to attack cancer cells. CARs bind the certain protein with specificity of a monoclonal antibody onto a T cell as an immunotherapy for cancer. CAR-Ts mostly derived from patients own blood (autologous) or from another healthy donor (allogenic) and are given to the patient by infusion. The receptors are called chimeric as they are fused of parts from different sources. CAR T-cell therapy is researched to find treatment of different types of cancer.
Global CAR-T therapies Market:
In 2017 the global CAR T market was valued at USD 72.0 million, and as per the “Coherent Market Insights” report, it is predicted to reach USD 8.5 Billion by 2028.
Global CAR-T Products in pipeline:
As per Cancer Research Institute (CRI), 404 chimeric antigen receptor (CAR) T cell therapies were in development pipeline till May 2018. In CAR T Cell Therapy US leads with 172 studies followed by 153 studies in China and collectively account for 80% of the global current landscape.
Global CAR T Targets in Cell Therapy:
CAR-T programs in clinical research involves more than 47 targets and they are mainly focused on CD19, BCMA, CD20, GD2, HER2, Mesothelin, CD22, CD33.
Key Acquisitions in CAR-T Market:
- Gilead Sciences acquired Kite Pharma: In August 2017, Gilead Sciences buy Kite Pharma for USD 11.9 billion in cash to benefit the FDA approved Kymriah.
- Celgene Corporation acquired Juno Therapeutics: Celgene Corporation agreed in Jan 2018 to acquire Juno Therapeutics for approximately USD 9 billion to boost CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics portfolio. Juno Therapeutics JCAR017’s is expected to add approximately $3 billion in peak sales and will significantly expect to strengthen Celgene’s lymphoma portfolio. Also its JCARH125 will enhance Celgene’s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma.
Other Key Player and strategic collaboration in CAR-T therapies:
Amgen: CAR T cell therapy programs by Amgen, with DLL3 in targeting small cell lung cancer and FLT3 in acute myeloid leukemia (AML) are in early phase. Pre-clinical data for Amgen’s DLL3 CAR T cell therapy and bispecific T cell engager (BiTE®) antibody constructs provides cell-based therapies for the treatment of SCLC. Cynomolgus monkey plasma cell gene signature is used by Amgen to quantify in vivo activity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma. Amgen also recently unveiled encouraging the data on their AMG-420 (ex Micromet/Boehringer) in five patients with multiple myeloma who achieved complete remission.
In Oct 2017, Amgen and CytomX Launch have also signed a 1.465B+ Cancer Immunotherapy Collaboration to codevelop a Probody T-cell-engaging bispecific against EGFRxCD3.